Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionTruist Financial Corp
Latest Disclosed Ownership7,701 shares
Latest Disclosed Value $ 2,548,056
Truist Financial Corp reports 26.14% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On April 27, 2026 - Truist Financial Corp filed a 13F-HR form disclosing ownership of 7,701 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $2,200,176 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 2, 2026 disclosing 6,105 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 26.14% during the quarter. The current value of the position is $1,939,112 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-27 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,701 1,596 26.14 2,548 4.99 0.0034
2026-02-02 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,105 -361 -5.58 2,428 -17.67 0.0032
2025-11-03 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,466 2,459 61.37 2,949 125.73 0.0040
2025-07-18 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,007 383 10.57 1,307 33.54 0.0019
2025-04-29 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,624 -774 -17.60 979 -5.42 0.0016
2025-01-31 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,398 2,539 136.58 1,035 102.35 0.0016
2024-11-13 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,859 131 7.58 511 21.96 0.0008
2024-08-21 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,728 -623 -26.50 420 19.37 0.0006
2024-05-13 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,351 -127 -5.13 351 -25.95 0.0005
2024-02-02 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,478 2,478 474 0.0008
2023-08-01 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -1,328 -100.00 0 -100.00
2023-05-05 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,328 -140 -9.54 266 -23.56 0.0005
2023-02-17 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,468 1,468 349 0.0006
2022-10-26 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -5,000 -100.00 0 -100.00
2022-07-22 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,000 -1,924 -27.79 729 -35.49 0.0013
2022-04-22 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,924 -671 -8.83 1,130 -12.27 0.0018
2022-02-14 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,595 992 15.02 1,288 3.37 0.0020
2021-11-05 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,603 40 0.61 1,246 12.05 0.0020
2021-08-16 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,563 838 14.64 1,112 37.62 0.0018
2021-05-17 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,725 3,972 226.58 808 254.39 0.0014
2021-11-19 2020-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,753 374 27.12 228 13.43 0.0004
2021-02-18 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,926 4,547 771 0.0014
2021-11-05 2020-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,379 -390 -22.05 201 -23.28 0.0004
2020-11-13 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,379 -390 201 0.0004
2021-11-16 2020-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,769 -168 -8.67 262 24.17 0.0006
2020-08-14 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,769 -168 262 0.0006
2021-11-05 2020-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,937 -201 -9.40 211 -13.88 0.0006
2020-05-15 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,937 -201 211 0.0006
2021-11-16 2019-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 2,138 2,138 245 0.0005
2020-02-14 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,138 245 0.0005
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.